ARTICLE | Company News
Icos and Abbott extend inflammation deal
June 22, 2000 7:00 AM UTC
ICOS acquired additional rights to ABT's technology and compounds to LFA-1 antagonists to treat inflammation. The companies formed the collaboration in 1995 under which ICOS had marketing rights in ca...